European Union And Industry Launch Massive Pharmaceutical R&D Program
Executive Summary
The European Commission and European drug makers have agreed to spend €2 billion, almost $3 billion, to develop technologies that can speed the development and delivery of new drugs to patients
You may also be interested in...
Viebacher: Drug R&D Future Is In Collaboration, But Safe Harbors Needed
Sanofi CEO says firms and other healthcare stakeholders all need to work together, but “no good deed goes unpunished.”
Pooled Antipsychotic Data Will Be Mined For Early Response Signals
A consortium of international drug companies hopes to leverage their pooled schizophrenia data into a means of determining which patient subgroups are most likely to respond to treatment during clinical trials.
Pooled Antipsychotic Data Will Be Mined For Early Response Signals
A consortium of international drug companies hopes to leverage their pooled schizophrenia data into a means of determining which patient subgroups are most likely to respond to treatment during clinical trials.